Table 1 Clinical characteristics of the cohort
Clinical Characteristics | n = 523 |
|---|---|
Median age (range), years | 59 (18–92) |
Median follow-up for patients without a metastatic event, years (range) | 7.5 (5.0–16.5) |
Recurrence/distant metastasis | 142/111 |
Median time to first recurrence, years (range) | 1.2 (0.0–10.0) |
AJCC stage | |
I (total) | 264 (50%) |
IA | 108 |
IB | 76 |
Unknown substagea | 80 |
II (total) | 93 (18%) |
IIA | 35 |
IIB | 26 |
IIC | 17 |
Unknown substage | 15 |
III (total) | 166 (32%) |
IIIA | 69 |
IIIB | 57 |
IIIC | 35 |
Unknown substage | 5 |
Breslow thickness | |
Median (range), mm | 1.2 (0.1–29.0) |
≤ 1 mm | 223 (43%) |
> 1 mm | 296 (56%) |
Unreported | 4 (1%) |
Mitotic index | |
< 1/mm2 | 99 (19%) |
≥ 1/mm2 | 240 (46%) |
Unreported | 184 (35%) |
Ulceration | |
Absent | 309 (59%) |
Present | 133 (26%) |
Unreported | 81 (15%) |
SLN status | |
Untested | 186 (36%) |
Negative | 180 (34%) |
Positive | 157 (30%) |
GEP Class | |
Class 1 | 314 (60%) |
Class 2 | 209 (40%) |